Phenytoin Sodium, Prompt Alternatives Compared
| Phenytoin Sodium, Prompt (phenytoin) | Xcopri (cenobamate) | Keppra (levetiracetam) |
|
|---|
| Phenytoin Sodium, Prompt (phenytoin) | Xcopri (cenobamate) | Keppra (levetiracetam) |
|
|||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Prescription only
Prescribed for Epilepsy, Seizures, Status Epilepticus, Neurosurgery, Seizure Prophylaxis During or Following Neurosurgery. Phenytoin Sodium, Prompt may also be used for purposes not listed in this... View more |
Prescription only
Xcopri is a brand name for cenobamate which may be used to reduce the frequency of partial seizures in adults. In some people, it reduces the frequency to zero. Clumsiness, dizziness, drowsiness... View more |
Prescription only
Keppra is an anticonvulsant that is used in conjunction with other medications for the treatment of certain types of seizures. It may cause drowsiness but it is less likely than some other... View more |
Related suggestions |
|||||||||||||||||||||||
| More about Phenytoin Sodium, Prompt (phenytoin) | More about Xcopri (cenobamate) | More about Keppra (levetiracetam) | ||||||||||||||||||||||||
| Ratings & Reviews | ||||||||||||||||||||||||||
|
Be the first to share your experience with this drug. |
Xcopri has an average rating of 8.6 out of 10 from a total of 37 ratings on Drugs.com. 81% of reviewers reported a positive effect, while 0% reported a negative effect. |
Keppra has an average rating of 5.7 out of 10 from a total of 307 ratings on Drugs.com. 43% of reviewers reported a positive effect, while 34% reported a negative effect. |
||||||||||||||||||||||||
| Side Effects Experienced by Users Side effects are reported in Drugs.com user reviews and not clinically verified. | ||||||||||||||||||||||||||
|
View all Xcopri side effects |
View all Keppra side effects |
|||||||||||||||||||||||||
| Drug Class | ||||||||||||||||||||||||||
| Generic Availability | ||||||||||||||||||||||||||
| Lower cost generic approved | ||||||||||||||||||||||||||
| Pricing and Coupons * Prices are without insurance | ||||||||||||||||||||||||||
View all Phenytoin Sodium, Prompt prices |
View all Xcopri prices |
View all Keppra prices |
||||||||||||||||||||||||
| Dosage Forms | ||||||||||||||||||||||||||
|
|
|
||||||||||||||||||||||||
| Brand Names | ||||||||||||||||||||||||||
| Other phenytoin brands include: Di-Phen, Dilantin, Phenytek, Phenytoin Sodium, Phenytoin Sodium, Extended Release |
N/A |
Other levetiracetam brands include: Elepsia XR, Keppra XR, Roweepra, Roweepra XR, Spritam | ||||||||||||||||||||||||
| Half Life Drug half-life is the time required for plasma concentration to reduce to half its original value. | ||||||||||||||||||||||||||
|
15 hours |
60 hours |
8 hours |
||||||||||||||||||||||||
| CSA Schedule 1 View glossary of CSA terms | ||||||||||||||||||||||||||
|
Not a controlled drug
Is not subject to the Controlled Substances Act. |
Some potential for abuse
Has a low potential for abuse relative to those in schedule 4. Has a currently accepted medical use in treatment in the United States. Abuse may lead to limited physical dependence or psychological dependence relative to those in schedule 4. |
Not a controlled drug
Is not subject to the Controlled Substances Act. |
||||||||||||||||||||||||
| Pregnancy Category | ||||||||||||||||||||||||||
|
Category D
Positive evidence of risk
See the full pregnancy warnings document. |
Summary unavailable. See the full pregnancy warnings document. |
Category C
Risk cannot be ruled out
See the full pregnancy warnings document. |
||||||||||||||||||||||||
| Drug Interactions | ||||||||||||||||||||||||||
|
A total of 855 drugs are known to interact with Phenytoin Sodium, Prompt:
|
A total of 582 drugs are known to interact with Xcopri:
|
A total of 238 drugs are known to interact with Keppra:
|
||||||||||||||||||||||||
| Alcohol/Food/Lifestyle Interactions | ||||||||||||||||||||||||||
|
|
|||||||||||||||||||||||||
| Disease Interactions | ||||||||||||||||||||||||||
| First Approval Date | ||||||||||||||||||||||||||
|
N/A |
November 21, 2019 |
November 30, 1999 |
||||||||||||||||||||||||
| WADA Class View classifications | ||||||||||||||||||||||||||
|
N/A |
N/A |
N/A |
||||||||||||||||||||||||
| More Information | ||||||||||||||||||||||||||
| Patient Resources | ||||||||||||||||||||||||||
| Professional Resources | ||||||||||||||||||||||||||
|
N/A |
||||||||||||||||||||||||||
| Related Treatment Guide | ||||||||||||||||||||||||||
1 The Controlled Substances Act (CSA) schedule information displayed applies to substances regulated under federal law. There may be variations in CSA schedules between individual states.
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.